目的 系統(tǒng)評價二肽基肽酶-4（DPP-4）抑制劑西格列汀對中國2型糖尿病腎病患者的保護作用。方法 計算機檢索中國知網(wǎng)（CNKI）、中國生物醫(yī)學文獻數(shù)據(jù)庫（CBM）、維普數(shù)據(jù)庫（VIP）、萬方數(shù)據(jù)庫等數(shù)據(jù)庫，并追溯納入文獻的參考文獻，時限為建庫至2017年3月。獲取西格列汀對中國2型糖尿病腎病的保護作用的隨機對照試驗（RCTs），采用RevMan 5.0軟件對各項指標進行Meta-分析。結果 共納入12篇RCT，包括糖尿病腎病患者788例。Meta-分析結果顯示：西格列汀組在降低血糖指標空腹血糖、糖化血紅蛋白、餐后2 h血糖及體質量指數(shù)，和腎臟功能指標尿白蛋白肌酐比值、尿微量白蛋白、高敏C反應蛋白、胱抑素等方面均優(yōu)于常規(guī)治療對照組，差異有統(tǒng)計學意義（MD<0，P<0.05）；在降低肌酐、尿白蛋白排泄率、β2-微球蛋白方面，兩組差異無統(tǒng)計學意義。結論 新型降血糖藥物DPP-4抑制劑西格列汀不僅可以降低血糖，還可以對糖尿病腎病患者腎臟起保護作用。

Objective To investigate the protective effects of sitagliptin as dipeptidyl peptidase-4 (DPP-4) inhibitor on kidney in patients with type 2 diabetes mellitus. Methods The related literatures in databases were searched including CNKI, WanFang, VIP, CBM and so on. Randomized controlled trials (RCTs) of sitagliptin for the treatment of type 2 diabetic nephropathy were included, data were collected with time limit from establishment to March, 2017 and also retrieved manually, Meta-analysis of the data was performed by using RveMan 5.0. Results Twelve RCTs were collected, including 788 diabetic nephropathy patients. The results of Meta-analysis showed that sitagliptin group can effectively reduce the FBG, HbA1c, 2 hPBG, BMI, ACR, mALB, hs-CRP, and Cys C (MD < 0, P<0.05) compared with the routine therapy group. There was no significant difference in index of β2-MG, Scr, and UAER between two groups. Conclusion As the new kind of hypolycemic agent, DPP-4 inhibitor sitagliptin can not only reduce the blood glucose but also protect the renal function of type 2 diabetic nephropathy patients.

重慶市社會事業(yè)與民生保障科技創(chuàng)新專項（cstc2015shmszx120073，cstc2017shmsA130105）；重慶市萬州科技計劃基金（201403055）